RF-1302

RF-1302 is a novel, potent dual inhibitor of PIM1 and FLT3 kinases currently in preclinical development for the treatment of acute myeloid leukemia (AML). Developed by Ruifu Therapeutics, the compound targets the PIM kinase family (specifically PIM1) and Fms-like tyrosine kinase 3 (FLT3), both of which are frequently upregulated or mutated in hematopoietic malignancies. In preclinical studies, RF-1302 demonstrated nanomolar inhibitory activity against its targets (PIM1 IC50: 1.0-2.3 nM; FLT3 IC50: 0.8-2.2 nM) and showed superior antitumor efficacy compared to approved FLT3 inhibitors like gilteritinib and midostaurin in AML xenograft models. Preclinical results suggest that RF-1302 may constitute a highly efficacious modality for the treatment of FLT3-mutant AML with minimal toxicity.